EIF2A and metabolic dysfunction-associated steatohepatitis: It was previously shown that despite PERK activation and eIF2α phosphorylation in the liver of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), downstream effectors such as CHOP remain inactive [40].